TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers report that the mitochondrial protein Miro1 was elevated in skeletal muscle from people with type 2 diabetes and impaired muscle response to insulin in experiments. Removing Miro1 restored insulin responsiveness in preclinical models, while an exercise trial in people found lower muscle Miro1 alongside improved insulin sensitivity. The findings identify a possible research target, not a proven treatment.
A study published in Nature Communications identifies Miro1, a protein found at higher levels in the skeletal muscles of people with type 2 diabetes, as a possible contributor to muscle insulin resistance. Researchers found that removing the protein restored insulin responsiveness in preclinical models, while an exercise trial in people with the disease found lower muscle Miro1 alongside improvements in insulin sensitivity.
Miro1, short for Mitochondrial Rho GTPase 1, sits on the outer membrane of mitochondria, cellular structures involved in energy production. The research team examined the protein in laboratory cells, preclinical models and people with type 2 diabetes. Their findings linked Miro1 buildup with a weaker muscle response to insulin, which helps regulate blood sugar.
In preclinical experiments, removing Miro1 restored insulin responsiveness in muscle. That result supports a direct role for the protein in the process in those models, but it does not establish that a Miro1-targeting treatment would work safely or effectively in people.
The human component was a randomized controlled trial involving participants with obesity and type 2 diabetes. Researchers compared aerobic exercise with standard medical care. Participants assigned to exercise had lower Miro1 levels in their muscles, alongside improved insulin sensitivity and muscle energy-producing capacity. The report does not establish that the Miro1 change alone caused those improvements.
How Miro1 May Affect Insulin Response
Insulin resistance in muscle is a central feature of type 2 diabetes: when muscle responds less effectively to insulin, the body has more difficulty regulating blood sugar. The findings point to Miro1 as one possible part of the biological pathway behind that problem, offering researchers a specific mechanism to investigate rather than treating insulin resistance as an unexplained outcome.
The exercise results also provide a possible molecular link between physical activity and improved insulin sensitivity. They do not change current care recommendations or show that manipulating Miro1 is a treatment. Instead, the work could guide further research into whether the protein can be safely targeted and whether its levels help explain differences in muscle response.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Withings BPM Connect Blood Pressure Monitor with Wi-Fi and Bluetooth
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
As an affiliate, we earn on qualifying purchases.
From Muscle Experiments to Participants
The study’s approach spans cell and preclinical research as well as a trial involving people. That range allowed the team to examine a possible mechanism and compare it with observations in people with type 2 diabetes. However, results across these settings answer different questions: removing Miro1 showed an effect in preclinical models, while the human trial tested exercise and measured associated changes.
Senior author Dr. John P. Kirwan conducted the research at LSU’s Pennington Biomedical Research Center and has since moved to the University of Oklahoma’s Harold Hamm Diabetes Center. Study first author Elizabeth Heintz was a doctoral candidate at Pennington Biomedical. Kirwan said the project traced Miro1 from cells and preclinical models to patients, while stressing its potential as a target for future work rather than an available therapy.
“For the field, this is a new therapeutic target.”
— Dr. John P. Kirwan, the study’s senior author
Treatment Potential Remains Untested
The findings do not show that directly reducing Miro1 can treat type 2 diabetes in people. Restoration of insulin responsiveness after Miro1 removal was demonstrated in preclinical models; the human trial examined exercise, not a drug or other intervention designed specifically to target the protein.
The report does not provide details such as the trial’s participant count, duration, or the size of the Miro1 and insulin-sensitivity changes. It is also unclear whether the protein’s elevated levels contribute to disease across a broad range of patients, or how much Miro1 reduction explains exercise-related benefits. Safety, effectiveness and feasibility of any future Miro1-targeting approach remain open questions.
Further Studies at Harold Hamm Center
Kirwan plans to continue the work at the Harold Hamm Diabetes Center, combining laboratory experiments with studies involving people. The next research steps will need to clarify how Miro1 affects muscle insulin response, test whether directly targeting the protein can produce a reliable effect, and assess safety before any treatment implications can be established.
Until such evidence is available, the study is best understood as a mechanistic research finding that adds a possible explanation for insulin resistance and exercise-related changes—not as a new clinical option. The published results do not specify a timeline for follow-up studies.
Key Questions
What is Miro1?
Miro1 is a protein on the outer membrane of mitochondria, structures inside cells involved in energy production. The study examined its levels and effects in skeletal muscle.
Does the study prove Miro1 causes type 2 diabetes?
No. The findings link elevated muscle Miro1 with impaired insulin response and show that removing it restored responsiveness in preclinical models. They do not establish that Miro1 is the sole cause of diabetes or prove the same effect in people.
Did exercise lower Miro1 in people?
In a randomized trial involving people with obesity and type 2 diabetes, the exercise group had lower muscle Miro1 levels, alongside improved insulin sensitivity and muscle energy-producing capacity. The reported association does not show that the Miro1 change alone caused the improvements.
Is there a treatment that targets Miro1?
The report does not describe an available Miro1-targeting treatment. Whether directly targeting the protein can lead to a safe and effective therapy for people remains to be studied.
Source: sciencedaily.com
